Abstract
Infections and sepsis are more common in cirrhotic than in the general population and constitute the commonest cause of sudden worsening and death. The diagnosis of systemic inflammatory syndrome and sepsis are challenging in cirrhotics due to an underlying a state of hyperdynamic circulation. Further, poor nutritional and bone marrow reserves lead to modest host immune response, the so called immunoparalysis state and the outcome of antibiotic therapy is suboptimal. In this review, a comprehensive description of current and emerging concepts in the pathogenesis and diagnosis of sepsis with importance to current and novel biomarkers for diagnosis of sepsis in cirrhosis is presented. Furthermore, novel treatment options and preventive strategies are discussed to improve the overall survival.
Similar content being viewed by others
References
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864–874
Bone RC, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101(6):1644–1655
Czura CJ. Merinoff symposium 2010: sepsis—an international call to action. Mol Med 2010;16(5–6):157–158
Zhang Q, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010;464:104–107
Duewell P, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357–1361
Hoque R, Sohail M, Malik A, et al. TLR9 and the NLRP3 inflammasome link acinar cell death with inflammation in acute pancreatitis. Gastroenterology 2011;141:358–369
McDonald B, McAvoy EF, Lam F, et al. Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids. J Exp Med 2008;205:915–927
Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140–148
Lee WY, Kubes P. Leukocyte adhesion in the liver: distinct adhesion paradigm from other organs. J Hepatol 2008;48:504–512
Bernsmeier C, Pop OT, Singanayagam A, Triantafyllou E, Patel VC, Weston CJ, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. Gastroenterology 2015;148:603–615
Soehnlein O, Kenne E, Rotzius P, Eriksson EE, Lindbom L. Neutrophil secretion products regulate anti-bacterial activity in monocytes and macrophages. Clin Exp Immunol 2008;151:139–145
Van Leeuwen HJ, van der Tol M, van Strijp JAG, Verhoef J, van Kessel KPM. The role of tumour necrosis factor in the kinetics of lipopolysaccharide-mediated neutrophil priming in whole blood. Clin Exp Immunol 2005;140:65–72
Mookerjee RP, Stadlbauer V, Lidder S et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007;46:831–840
Reddy RC, Chen GH, Tekchandani PK, Standiford TJ. Sepsis induced immunosuppression: from bad to worse. Immunol Res 2001;24:273–287
Bellot P, Garcia-Pagan JC, Frances R, Abraldes JG, Navasa M, Perez-Mateo M, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 2010;52:2044–2052
Ono Y, Watanabe T, Matsumoto K, et al. Opsono-phagocytic dysfunction in patients with liver cirrhosis and low responses to tumor necrosis factor-alpha and lipopolysaccharide in patients’ blood. J Infect Chemother 2004;10:200–207
Berry PA, Antoniades CG, Carey I, McPhail MJ, Hussain MJ, Davies ET, Wendon JA, Vergani D. Severity of the compensatory anti-inflammatory response determined by monocyte HLA-DR expression may assist outcome prediction in cirrhosis. Intensive Care Med 2011;37(3):453–460
Wherry EJ. T cell exhaustion. Nature Immunol 2011;12:492–499
Guignant C, et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 2011;15:R99
Monneret G, et al. Marked elevation of human circulating CD4 + CD25 + regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 2003;31:2068–2071
Dirchwolf M, Ruf AE. Role of systemic inflammation in cirrhosis: from pathogenesis to prognosis. World J Hepatol 2015;7(16):1974–1981
Elefsiniotis IS, Skounakis M, Vezali E, et al. Clinical significance of serum PCT levels in patients with acute or chronic liver disease. Eur J Gastroenterol Hepatol 2006;18:525–530
Cervoni JP, Thévenot T, Weil D, Muel E, Barbot O, Sheppard F, et al. C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol 2012;56(6):1299–1304
Li CH, Yang R, Pang JH, et al. PCT as a biomarker for bacterial infection in patients with liver cirrhosis in the emergency department. Acad Emerg Med 2011;18:121–126
Guignant C, Voirin N, Venet F, et al. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med 2009;35:1859–1867
Wu HP, Chen CK, Chung K et al. Plasma transforming growth factor-b1 level in patients with severe community-acquired pneumonia and association with disease severity. J Formos Med Assoc 2009;108:20–27
Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005;11(5):234–238
Naitoh K, Shirakawa K, Hirose J, Nakamura M, Takeuchi T, Hosaka Y, et al. The new sepsis marker, sCD14-ST (PRESEPSIN), induction mechanism in the rabbit sepsis models. Sepsis 2010;14(Suppl 2):19
Müller MC, Meijers JC, Vroom MB, Juffermans NP. Utility of thrombo elastography and/or thrombo elastometry in adults with sepsis: a systematic review. Crit Care 2014;18(1):R30
Philips CA, Choudhury AK, Sahney A, Maiwall R, Mitra LG, Sarin SK. Comparison and outcomes of 5 % albumin vs 0.9 % normal saline fluid resuscitation in cirrhotics presenting with sepsis induced hypotension—a randomized controlled trial—fluid resuscitation in septic shock in cirrhosis (FRISC Protocol) hepatology. Pres Plenary Clin Hepatol 2015;62:261A–265A
Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580–637
Arabi YM, Dara SI, Memish Z, et al. Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis. Hepatology (Baltimore, Md) 2012;56(6):2305–2315
Acevedo J, Silva A, Prado V, Fernandez J. The new epidemiology of nosocomial bacterial infections in cirrhosis: therapeutical implications. Hepatol Int 2013;7:72–79
Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403–409
Fernández J, Monteagudo J, Bargallo X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005;42:627–634
Rifai K, Kribben A, Gerken G, et al. Extracorporeal liver support by fractionated plasma separation and adsorption (PROMETHEUS) in patients with acute-on-chronic liver failure (HELIOS study): a prospective randomized controlled multicenter study. J Hepatol 2010;52:S3
Garnacho-Montero J, Escoresca-Ortega A, Fernández-Delgado E. Antibiotic de-escalation in the ICU: how is it best done? Curr Opin Infect Dis 2015;28(2):193–198
Alves-Filho JC, et al. Neutrophil paralysis in sepsis. Shock 2010;34(Suppl 1):15–21
Meisel C, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009;180:640–648
Chang KC, et al. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care 2013;17:R85
Inoue S, et al. Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock 2011;36:38–44
Tritto G, Bechlis Z, Stadlbauer V, Davies N, Francés R, Shah N, et al. Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. J Hepatol 2011;55:574–581
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13:862–874
Liu B, Chen YX, Yin Q, Zhao YZ, Li CS. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit Care 2013;17:R244
Anastasiou J, Williams R. When to use antibiotics in the cirrhotic patient? The evidence base. Ann Gastroenterol 2013;26(2):128–131
Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012;56 Suppl 1:S1–S12
Hutchins NA, Unsinger J, Hotchkiss RS, Ayala A. The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med 2014;20:224–233
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Philips, C.A., Sarin, S.K. Sepsis in cirrhosis: emerging concepts in pathogenesis, diagnosis and management. Hepatol Int 10, 871–882 (2016). https://doi.org/10.1007/s12072-016-9753-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-016-9753-2